摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-aminophenyl)propanoic acid | 21762-11-8

中文名称
——
中文别名
——
英文名称
2-(3-aminophenyl)propanoic acid
英文别名
α-(3-Aminophenyl)propionsaeure;(+/-)-2-(3-amino-phenyl)-propionic acid;(+/-)-2-(3-Amino-phenyl)-propionsaeure;(3-aminophenyl)propionic acid;2-(m-aminophenyl)propionic acid
2-(3-aminophenyl)propanoic acid化学式
CAS
21762-11-8
化学式
C9H11NO2
mdl
——
分子量
165.192
InChiKey
UMVOCNFWVVRKKE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    63.3
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Protein-tyrosine phosphatase inhibitors and uses thereof
    申请人:——
    公开号:US20040214870A1
    公开(公告)日:2004-10-28
    The present invention is directed to compounds of formula (I), 1 or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.
    本发明涉及式(I)的化合物,或其药用适宜盐或前药,用于选择性抑制蛋白酪氨酸磷酸酶-1B(PTP1B),并且用于治疗由过度表达或改变的蛋白酪氨酸磷酸酶1B引起的疾病。
  • [EN] NOVEL COMPOUNDS<br/>[FR] COMPOSÉS INÉDITS
    申请人:GLAXO GROUP LTD
    公开号:WO2011038572A1
    公开(公告)日:2011-04-07
    The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
    本发明公开了抑制LRRK2激酶活性的新化合物,其制备过程,含有它们的组合物,以及在治疗以LRRK2激酶活性为特征的疾病中的应用,特别是帕金森病和阿尔茨海默病。
  • NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
    申请人:Boyd A. Vincent
    公开号:US20070021434A1
    公开(公告)日:2007-01-25
    The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.
    本公开提供了基于酰胺的非核苷类化合物,具有抗Hepacivirus活性,例如丙型肝炎病毒(HCV),合成这类化合物的方法和中间体,以及在各种情境中使用这些化合物的方法,包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
  • COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
    申请人:Cameron Dale Russell
    公开号:US20080171783A1
    公开(公告)日:2008-07-17
    The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.
    本公开提供了基于酰胺的非核苷类化合物,具有对内源聚合酶(如聚合酶α和聚合酶γ)的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途,例如良性或恶性肿瘤,更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
  • [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2014060113A1
    公开(公告)日:2014-04-24
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及一种具有公式(I)的新化合物,能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮氨酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
查看更多